PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2020.01252021271110-124<i>Lactobacillus</i> attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosisNa Young Lee, Min Jea Shin, Gi Soo Youn, Sang Jun Yoon, Ye Rin Choi, Hyeong Seop Kim, Haripriya Gupta, Sang Hak Han, Byoung Kook Kim, Do Yup Lee, Tae Sik Park, Hotaik Sung, Byung Yong Kim, Ki Tae Sukhttp://e-cmh.org/upload/pdf/cmh-2020-0125.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2020.0125, http://e-cmh.org/upload/pdf/cmh-2020-0125.pdf
Non-Alcoholic Fatty Liver Disease - Molecular Bases, Prevention and Treatment10.5772/intechopen.711612018Noninvasive Evaluation of Fibrosis and Steatosis in Nonalcoholic Fatty Liver Disease by Elastographic MethodsMonica Lupsor-Platonhttp://www.intechopen.com/download/pdf/58040
Nutrients10.3390/nu14010076202114176Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and ApoptosisJinwang Li, Siyu Xie, Wendi Tenghttps://www.mdpi.com/2072-6643/14/1/76/pdf
Hepatology10.1002/hep.271732014602565-575Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver diseasePierre Bedossa, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.27173, http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.27173/fullpdf
Clinical Gastroenterology and Hepatology10.1016/j.cgh.2017.11.0402018163341-342Do Zones of Hepatic Steatosis Associate With Subtypes and Progression of Nonalcoholic Fatty Liver Disease in Children?Veeral Ajmera, Rohit Loombahttps://api.elsevier.com/content/article/PII:S1542356517314131?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1542356517314131?httpAccept=text/plain
Clinical and Molecular Hepatology10.3350/cmh.2022.03262023291163-164Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”Yuanbin Liu, Mingkai Chenhttp://e-cmh.org/upload/pdf/cmh-2022-0326.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2022.0326, http://e-cmh.org/upload/pdf/cmh-2022-0326.pdf
Gastroenterology10.1016/s0016-5085(11)62918-120111405S-702Interleukin-17 Integrates Hepatic Steatosis and Inflammation in Nonalcoholic Fatty Liver DiseaseXiong Mahttps://api.elsevier.com/content/article/PII:S0016508511629181?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508511629181?httpAccept=text/plain
Clinical and Experimental Gastroenterology10.2147/ceg.s3173402021Volume 14269-275Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease?Celal Ulasoglu, Zeynep Nilufer Tekin, Kubra Akan, Arda Yavuzhttps://www.dovepress.com/getfile.php?fileID=70438, https://www.dovepress.com/getfile.php?fileID=70438
Clinical Liver Disease10.1002/cld.66201214129-130Management of nonalcoholic fatty liver disease in childrenJean P. Mollestonhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcld.66, http://onlinelibrary.wiley.com/wol1/doi/10.1002/cld.66/fullpdf
Hepatology10.1002/hep.20973200643S1S99-S112Nonalcoholic fatty liver disease: From steatosis to cirrhosisGeoffrey C. Farrell, Claire Z. Larterhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.20973, https://onlinelibrary.wiley.com/doi/full/10.1002/hep.20973